New Hope for Herpes: Assembly Bio Data Hints at Monthly Treatment

SOUTH SAN FRANCISCO, CA – April 09, 2026 – In a significant development for the millions affected by recurrent genital herpes, Assembly Biosciences today announced that positive early-stage clinical data for two investigational long-acting therapies will be showcased at a major European medical conference. The news signals a potential paradigm shift in a therapeutic area that has seen no new classes of drugs approved in over two decades.

The biotechnology company revealed that promising Phase 1b data for its drug candidates, ABI-5366 and ABI-1179, have been accepted for presentation at the 2026 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in Munich. The selection, which includes a prestigious oral presentation for ABI-5366 and a late-breaker slot for ABI-1179, underscores the clinical relevance of the findings and has generated cautious optimism for a condition that carries a heavy physical and psychological burden.

“The selection of ABI-5366 for oral presentation at ESCMID underscores the strength and clinical relevance of the data generated to date, including additional results from the monthly dosing cohort,” said Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio, in a statement. “We are also pleased to see the first scientific presentation of Phase 1b data for ABI-1179 recognized as a late-breaker presentation, which highlight its potential as a long-acting therapeutic option for patients with recurrent genital herpes.”

A Potential Game-Changer for Patients

For the more than four million people in the U.S. and Europe who suffer from recurrent genital herpes, the current standard of care has long been a source of frustration. Existing treatments, primarily nucleoside analogs like acyclovir and valacyclovir, must be taken daily as a suppressive therapy. While they can reduce the frequency and severity of outbreaks, they are only partially effective—preventing recurrence in only about one-third of individuals—and do not completely stop the asymptomatic viral shedding that can lead to transmission.

The burden of daily medication, coupled with the anxiety of potential outbreaks and social stigma, significantly impacts patients' quality of life. Research indicates that the condition can lead to psychological distress, loss of self-esteem, and even reduced workplace productivity. The prospect of a long-acting oral therapy that could be taken weekly or even monthly represents a monumental leap forward.

Assembly Bio’s candidates aim to fill this long-standing gap. The upcoming presentations will feature data from a monthly dosing cohort for ABI-5366, directly addressing the demand for a more convenient and less burdensome treatment regimen. If successful in later-stage trials, such a therapy could dramatically improve adherence and provide patients with a newfound sense of control over the chronic infection.

The Science of a Novel Approach

At the heart of this potential breakthrough is a novel mechanism of action. Both ABI-5366 and ABI-1179 are herpes simplex virus (HSV) helicase-primase inhibitors. Unlike the decades-old nucleoside analogs that target the virus's DNA polymerase, these drugs block the helicase-primase enzyme complex—a molecular machine essential for unwinding the viral DNA to initiate its replication. This complex is crucial for viral growth and has no human equivalent, making it an ideal and highly specific antiviral target.

This distinct mechanism not only offers a new line of attack but also holds the potential to be effective against viral strains that have developed resistance to older drugs, a growing concern particularly in immunocompromised patients. The helicase-primase inhibitor class has already gained clinical validation, with another drug, pritelivir, receiving FDA Breakthrough Therapy Designation for resistant HSV infections and amenamevir approved in Japan.

While the full data will be unveiled at ESCMID, previous interim results for ABI-5366 have already set a high bar. The company reported a statistically significant 94% reduction in the rate of viral shedding compared to placebo over a 29-day period, a figure that suggests potent antiviral activity and supports the feasibility of less frequent dosing. The upcoming presentations are expected to provide a more complete picture of the safety, efficacy, and long-acting pharmacokinetic profile of both drug candidates.

A Strategic Alliance with Antiviral Titan Gilead

The journey of these promising candidates is not being navigated by Assembly Bio alone. In a major vote of confidence, antiviral giant Gilead Sciences has already stepped in to shepherd the drugs through further development. The two compounds are exclusively licensed to Gilead as part of a 12-year collaboration established in 2023, a partnership designed to leverage Assembly Bio’s innovative virology platform and Gilead’s extensive development and commercialization power.

Last year, Gilead exercised its option to exclusively license the entire HSV program, including both ABI-5366 and ABI-1179, for a $35 million payment. This move placed the sole responsibility for all future clinical development and commercialization squarely in the hands of a company renowned for its successes in HIV, hepatitis, and other viral diseases. For Assembly Bio, a smaller biotech firm, the deal provided a significant capital infusion and a clear pathway to market. For Gilead, it represents a strategic investment to fortify its antiviral pipeline and enter a market with a substantial unmet need.

This partnership model—where a nimble biotech's discovery engine is fueled by a pharmaceutical leader's resources—is a classic industry strategy for accelerating medical innovation. Gilead's early and decisive commitment suggests a strong belief in the scientific and commercial potential of the helicase-primase inhibitor platform to deliver the first new class of genital herpes treatment in a generation.

As the medical community awaits the full data from Munich, the focus remains on the future. While ABI-5366 and ABI-1179 are still investigational and years away from potential approval, the upcoming presentations mark a critical milestone. They offer a tangible glimpse into a future where the management of recurrent genital herpes could be transformed, freeing patients from the constraints of daily medication and offering more effective, long-term control of the virus.